{"title_page": "Alacizumab pegol", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 477315023\n| image = \n<!-- Monoclonal antibody data -->\n| type = mab\n| mab_type = F(ab')2\n| source = zu/o\n| target = [[VEGFR2]]\n<!-- Clinical data -->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->\n| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status = \n| routes_of_administration = \n<!-- Pharmacokinetic data -->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion = \n<!-- Identifiers -->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 934216-54-3\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = ZL9780F883\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n<!-- Chemical data -->\n| chemical_formula = \n| molecular_weight = \n}}\n'''Alacizumab pegol''' is an [[antineoplastic]] agent. Chemically, it is a [[pegylated]] [[F(ab')2|F(ab')<sub>2</sub> fragment]] of a [[monoclonal antibodies|monoclonal antibody]].<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], ''World Health Organization''.</ref>\n\n== References ==\n<references/>\n\n{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}\n{{Growth factor receptor modulators}}\n\n[[Category:Monoclonal antibodies]]\n[[Category:Experimental cancer drugs]]\n\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 477315023\n| image = \n<!-- Monoclonal antibody data -->\n| type = mab\n| mab_type = F(ab')2\n| source = zu/o\n| target = [[VEGFR2]]\n<!-- Clinical data -->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->\n| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status = \n| routes_of_administration = \n<!-- Pharmacokinetic data -->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion = \n<!-- Identifiers -->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 934216-54-3\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = \n| DrugBank_Ref = {{drugbankcite|correct|drugbank}}\n| DrugBank = \n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = none\n<!-- Chemical data -->\n| chemical_formula = \n| molecular_weight = \n}}\n'''Alacizumab pegol''' is an [[antineoplastic]] agent. Chemically, it is a [[pegylated]] [[F(ab')2|F(ab')<sub>2</sub> fragment]] of a [[monoclonal antibodies|monoclonal antibody]].<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], ''World Health Organization''.</ref>\n\n== References ==\n<references/>\n\n{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}\n{{Growth factor receptor modulators}}\n\n[[Category:Monoclonal antibodies]]\n[[Category:Experimental cancer drugs]]\n\n\n{{monoclonal-antibody-stub}}\n{{antineoplastic-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Alacizumab_pegol"}
